Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies

Chimeric antigen receptor (CAR) T-cell therapy is highly effective in the treatment of B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoma, providing alternative therapeutic options for patients who failed to respond to conventional treatment or relapse. Moreover, it can bridge other therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xinjie, Sun, Qihang, Liang, Xiaoqian, Chen, Zitong, Zhang, Xiaoli, Zhou, Xuan, Li, Meifang, Tu, Huilin, Liu, Yu, Tu, Sanfang, Li, Yuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863137/
https://www.ncbi.nlm.nih.gov/pubmed/31798590
http://dx.doi.org/10.3389/fimmu.2019.02664
_version_ 1783471698226446336
author Xu, Xinjie
Sun, Qihang
Liang, Xiaoqian
Chen, Zitong
Zhang, Xiaoli
Zhou, Xuan
Li, Meifang
Tu, Huilin
Liu, Yu
Tu, Sanfang
Li, Yuhua
author_facet Xu, Xinjie
Sun, Qihang
Liang, Xiaoqian
Chen, Zitong
Zhang, Xiaoli
Zhou, Xuan
Li, Meifang
Tu, Huilin
Liu, Yu
Tu, Sanfang
Li, Yuhua
author_sort Xu, Xinjie
collection PubMed
description Chimeric antigen receptor (CAR) T-cell therapy is highly effective in the treatment of B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoma, providing alternative therapeutic options for patients who failed to respond to conventional treatment or relapse. Moreover, it can bridge other therapeutic strategies and greatly improve patient prognosis, with broad applicable prospects. Even so, 30–60% patients relapse after treatment, probably due to persistence of CAR T-cells and escape or downregulation of CD19 antigen, which is a great challenge for disease control. Therefore, understanding the mechanisms that underlie post-CAR relapse and establishing corresponding prevention and treatment strategies is important. Herein, we discuss post-CAR relapse from the aspects of CD19-positive and CD19-negative and provide some reasonable prevention and treatment strategies.
format Online
Article
Text
id pubmed-6863137
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-68631372019-12-03 Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies Xu, Xinjie Sun, Qihang Liang, Xiaoqian Chen, Zitong Zhang, Xiaoli Zhou, Xuan Li, Meifang Tu, Huilin Liu, Yu Tu, Sanfang Li, Yuhua Front Immunol Immunology Chimeric antigen receptor (CAR) T-cell therapy is highly effective in the treatment of B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoma, providing alternative therapeutic options for patients who failed to respond to conventional treatment or relapse. Moreover, it can bridge other therapeutic strategies and greatly improve patient prognosis, with broad applicable prospects. Even so, 30–60% patients relapse after treatment, probably due to persistence of CAR T-cells and escape or downregulation of CD19 antigen, which is a great challenge for disease control. Therefore, understanding the mechanisms that underlie post-CAR relapse and establishing corresponding prevention and treatment strategies is important. Herein, we discuss post-CAR relapse from the aspects of CD19-positive and CD19-negative and provide some reasonable prevention and treatment strategies. Frontiers Media S.A. 2019-11-12 /pmc/articles/PMC6863137/ /pubmed/31798590 http://dx.doi.org/10.3389/fimmu.2019.02664 Text en Copyright © 2019 Xu, Sun, Liang, Chen, Zhang, Zhou, Li, Tu, Liu, Tu and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Xu, Xinjie
Sun, Qihang
Liang, Xiaoqian
Chen, Zitong
Zhang, Xiaoli
Zhou, Xuan
Li, Meifang
Tu, Huilin
Liu, Yu
Tu, Sanfang
Li, Yuhua
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
title Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
title_full Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
title_fullStr Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
title_full_unstemmed Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
title_short Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
title_sort mechanisms of relapse after cd19 car t-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863137/
https://www.ncbi.nlm.nih.gov/pubmed/31798590
http://dx.doi.org/10.3389/fimmu.2019.02664
work_keys_str_mv AT xuxinjie mechanismsofrelapseaftercd19cartcelltherapyforacutelymphoblasticleukemiaanditspreventionandtreatmentstrategies
AT sunqihang mechanismsofrelapseaftercd19cartcelltherapyforacutelymphoblasticleukemiaanditspreventionandtreatmentstrategies
AT liangxiaoqian mechanismsofrelapseaftercd19cartcelltherapyforacutelymphoblasticleukemiaanditspreventionandtreatmentstrategies
AT chenzitong mechanismsofrelapseaftercd19cartcelltherapyforacutelymphoblasticleukemiaanditspreventionandtreatmentstrategies
AT zhangxiaoli mechanismsofrelapseaftercd19cartcelltherapyforacutelymphoblasticleukemiaanditspreventionandtreatmentstrategies
AT zhouxuan mechanismsofrelapseaftercd19cartcelltherapyforacutelymphoblasticleukemiaanditspreventionandtreatmentstrategies
AT limeifang mechanismsofrelapseaftercd19cartcelltherapyforacutelymphoblasticleukemiaanditspreventionandtreatmentstrategies
AT tuhuilin mechanismsofrelapseaftercd19cartcelltherapyforacutelymphoblasticleukemiaanditspreventionandtreatmentstrategies
AT liuyu mechanismsofrelapseaftercd19cartcelltherapyforacutelymphoblasticleukemiaanditspreventionandtreatmentstrategies
AT tusanfang mechanismsofrelapseaftercd19cartcelltherapyforacutelymphoblasticleukemiaanditspreventionandtreatmentstrategies
AT liyuhua mechanismsofrelapseaftercd19cartcelltherapyforacutelymphoblasticleukemiaanditspreventionandtreatmentstrategies

Ejemplares similares